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A b s t r a c t
Introduction: Colorectal cancer is the third most common type of non-skin cancer
in men (after prostate and lung cancer) and women (after breast and lung
cancer). The mitochondrion conventionally is often thought to be an organelle
specific to energy metabolism. It is in fact multifunctional and has been implicated
in many diseases, including cancer. Alterations in the non-coding displacement
loop of mitochondrial DNA are present in many types of cancer. In another word
this loop has been shown to be a mutation “hot spot” in human cancers.
Material and methods: To assess the relationship between mitochondrial DNA
haplogroups and colorectal cancer, we sequenced the mitochondrial DNA
hypervariable segment I in a study population that comprised 95 cases (55 male,
40 female) and 100 unrelated healthy individuals as a control group. Haplotypes
were assigned according to the West Eurasian mtDNA genealogy.
Results: We found that haplogroup K is more frequent in colorectal patients
than healthy individuals. That means haplogroup K is significantly more abundant
in colorectal cancer patients (P=0.001).
Conclusions: In this study we found a significant association of haplogroup K
with colorectal cancer in Iranian patients so our finding suggests that mitochondrial
genetic background plays a role in modifying an individual’s risk for colorectal cancer.
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Introduction
Colorectal cancer (CRC) is a common lethal disease. CRC is the second
leading cause of cancer death in both sexes, accounting for 10 to 11% of cancer
deaths overall; it is the third most common in both men and women [1].
Approximately one in three people who develop CRC die of this disease.
A mitochondrial haplogroup is a cluster of phylogenetically related
mitochondrial genotypes (haplotypes). These haplogroups are defined by
ancient mutations [2]. These changes appeared and survived; therefore, they
could not be deleterious mutations. Most of them probably did not have
a phenotypic effect and were neutral. Some of them had a beneficial effect
and were positively selected. However, this positive effect was related to
a particular environment and nowadays, in other environmental conditions,
may have different effects on the phenotype [1-3]. In others words human
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haplogroups are defined by special polymorphisms
in human mitochondrial DNA (mtDNA). These
haplogroups trace the matrilineal inheritance
of modern humans back to human origins in Africa
and the subsequent spread across the globe.
Haplogroups could have important implications
for understanding the relationship between
mutability of the mitochondrial genome and disease
[4, 5]. There is growing evidence that certain mtDNA
clusters are associated with distinct disorders [6, 7].
Human mtDNA is composed of a 16.6 kb,
double-stranded, closed and circular DNA molecule. It is
independent of the nuclear genome. Human mtDNA
contains genes encoding 13 polypeptides involved in
oxidative phosphorylation (OXPHOS), 2 rRNAs, and a set
of 22 tRNAs essential for protein synthesis in
mitochondria [8]. All of the mitochondrial protein coding
genes encode subunits of the OXPHOS enzymes that
are responsible for the energy generating pathway. In
addition, mtDNA contains a non-coding region called
a displacement loop (D-loop), which is involved in
the control of replication and transcription of mtDNA [9].
The D-loop is a region of 1124 base pairs (position 16024-
576 on the mtDNA), which acts as a promoter for both
heavy and light strands of mtDNA and contains essential
transcription and replication elements [9]. 
This loop has been shown to be a mutation “hot
spot” in human cancers, and it contains two
hypervariable segment (HVS-I at positions 16024-
16383 and HVS-II at positions 57-372) [10]. Because
the D-loop is involved in the control of replication
and transcription of mtDNA, mutations in this region
might cause a decrease in the copy number or
alteration in gene expression of the mitochondrial
genome, which would further deregulate
mitochondrial metabolism and OXPHOS.
Most of the mutations observed in both mtDNA
coding and non-coding regions have occurred in
pre-existing haplogroups and have defined
the individual mtDNA types or haplotypes [11]. 
Material and methods
To investigate the involvement of mtDNA
haplogroups in determining susceptibility to colon
cancer, we sequenced the mtDNA HVS-I of 95
Iranian CRC patients. Also we sequenced 100
unrelated healthy individuals with neither apparent
genetic or metabolic disorders nor any type
of cancer as normal subjects (Table I).
Demographic, clinical and tumour-related
characteristics of patients were recorded based on
their hospital documents. These parameters included
gender, age at diagnosis, place and date of birth and
tumour-related factors such as location, stage, degree
of differentiation and mucus production.
The local ethical committee approved the research
proposal before beginning the project and all
of the patients were interviewed to trace their family
history of cancer including occurrence of malignancy
in the family, type of cancer and the age at diagnosis
of the affected family member, and a consent form
was taken from each patient to do this research.
The control group consisted of 100 unrelated
Iranian people, who visited the blood donor clinic in
Tehran. They answered an extensive questionnaire
regarding their current health and medical history,
and we chose healthy individuals with neither
apparent genetic or metabolic disorders nor any type
of cancer. All of the patients and controls were
informed of the aims of the study and gave their
informed consent to the genetic analysis. The mean
age was 49.3 for patients and 45.6 for normal
controls. Peripheral blood samples were obtained
and DNA was purified after lyses of white blood cells
by use of a DNA extraction kit (DNAfast DNA
Extraction Kit, Genefanavaran, Tehran, Iran).
PCR amplification was carried out in a final volume
of 25 μl containing 200-300 ng total DNA, 70 μM
of each dNTP, 10 pmol of each primer, 2.5 mM MgCl2,
1 U of Taq DNA polymerase (Cinnagen, Tehran, Iran)
and 2.5 μl of PCR buffer. The PCR profile was as
follows: 94°C for 5 min, 30 cycles of 94°C for
50 s, 57°C for 50 s and 72°C for 50 s, followed by 72°C
for 10 min. The sequenced products were analyzed
on 1.5% agarose gel. The amplified sequences
of some samples which demonstrate the 1339 bp
fragment of the D loop region are shown in Figure 1.
Meanwhile, mt15340F primer (5'-ATTCTTGCACGA
AACGGGATC -3') located at 15340-15360 bp and
mt91R primer (5'-GCTCCGGCTCCAGCGTCTCG -3')
located at 110-91 bp of the mtDNA were used to
amplify a 1339 bp sequence encompassing HVS-I in
the D-loop of the mtDNA to fetch the 359 bp
sequence (16,024–16,383 nt) for HVS-I. The nucleotide
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Figure 1. Demonstration of amplified 1339 bp D-loop
region containing the HVS I region of a CRC patient.
The HVS-I region of each CRC sample and control
was amplified and directly sequenced and analyzed
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sequence of the amplicon was directly determined
by automated sequencing on an ABI 3700 machine,
using primer mt91R (Gene Fanavaran, Macrogene
Seoul, Korea). The obtained mtDNA sequences were
aligned with a multiple sequence alignment interface
CLUSTAL X with comparison to revised Cambridge
Reference Sequence (rCRS) (http://www.gen.emory.edu
/mitomap/ mitoseq.html). 
Haplotypes were assigned according to the West
Eurasian mtDNA genealogy [12]. Assignment
of the haplogroups is carried out using the following
algorithm (for brevity all numbering is according to
ref. [13] minus 16,000 in the control region
of mtDNA): 069T 126C 223C assigned to haplogroup
J; 126C 223C 294T assigned to T; 129A 223T 391A
assigned to I; 223T 292T assigned to W;
189C 223T 278T assigned to X; 223C 224C 311C
assigned to K; 362C assigned to D; 290T and 319A
assigned to A; 223T assigned to R; 304C assigned
to H1, 189C and 356T assigned to H3, 129A assigned
to H4, 221T assigned to H5; 162G assigned to
H8; 223C 249C and either 189C or 327T assigned to
U1; 129C 223C assigned to U2: 223C 343G assigned
to U3; 223C 356C assigned to U4; 223C 270T
assigned to U5; 172C 219G 223C assigned to
U6; 223C 318T assigned to U7; 223C 298C assigned
to V; 223T 278T 390A assigned to L2;
and 187T 189C 223T 278T 311C assigned to L1.
Statistical analysis 
Fisher’s exact probability test was used to
examine the association between the two groups.
A P-value of less than 0.05 determines
the statistical significance of the relationship
between CRC and the proportion of mtDNA with
the mitochondrial haplogroups.
Results
Since mitochondria play pivotal roles in
carcinogenesis and metabolism of cancer cells [12],
we analyzed the correlation between cancers and
mitochondrial haplogroups. We examined the relation-
ship between colorectal cancer and each of 9 major
mitochondrial haplogroups in Iranian CRC patients.
The mtDNA haplogroups of 95 colon cancer
patients and 100 control subjects were determined
by direct sequencing of mtDNA HVS I. 
The studies of mtDNA polymorphism were based
either on sequence variation in the control region,
usually only the HVS-I segment, or RFLP analysis
of the coding region [12-14]. mtDNA polymorphisms
are associated with numerous chronic diseases,
including diabetes, Alzheimer’s disease, Parkinson’s
disease, bipolar disorders, and cancer.
Our result for the haplogroups for 95 colon cancer
patients and 100 normal subjects shows that
haplogroup K is more frequent in CRC patients than
healthy individuals. The results are demonstrated in
Table I. In this table the distribution of different
mtDNA haplogroups in the studied CRC patients as
well as in the population of normal controls is listed
and the statistical parameter of the P-values are
calculated and shown.
The characteristics of the tested CRC patients
and the normal controls including age and sex are
depicted in Table II.
Discussion
As demonstrated in Table I, haplogroup K is
significantly more abundant in CRC patients
(P=0.001). This finding is suggestive of a significant
role for mtDNA haplotype in cancer development
and risk. Our data showed that patients with
colorectal cancer clustered in haplogroup K have
a significantly higher frequency when compared
with controls, implicating a possible association
of haplogroup K with colorectal cancer. We
concluded that mitochondrial polymorphisms in
haplogroup K might play a genetic role in
predisposing to colorectal cancer. Substitutions in
the D-loop may be part of a haplotype with
mutations elsewhere in the mtDNA. Also mtDNA
HVS-I mutations may cause energy deficiency in
stressful situations during a vulnerable develo-
pmental period [15]. The hypothesis is that on their
own some polymorphisms are selectively neutral,
Parameters No. of patients No. of controls
Age • ≤50 28 68
• >50 67 32
Sex • Male 55 72
• Female 40 28
Tumour differentiation Adenocarcinoma –
Table II. Characteristics of 95 colorectal cancer
patients and 100 normal controls
mtDNA Colon cancer Control P-value
haplogroups patients [%] subjects [%]
H 4/95 (4.2) 7/100 (7) 0.538
D 8/95 (8.42) 13/100 (13) 0.359
L 12/95 (12.63) 15/100 (15) 0.682
J 13/95 (13.68) 19/100 (19) 0.339
T 10/95 (10.52) 15/100 (15) 0.396
U 6/95 (6.31) 3/100 (3) 0.321
K 9/95 (9.47) 0/100 (0) 0.001*
A 2/95 (2.10) 1/100 (1) 0.613
R 20/95 (21.05) 18/100 (18) 0.717
*Other 16/95 (16.84) 9/100 (9) 0.133
Table I. Distribution of mtDNA haplogroups among
colon cancer patients and normal controls
*Statistically significant; Others – haplogroup I, W, X, and V
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but in specific combinations they act in
a synergistic, deleterious manner with established
pathogenic mtDNA mutations to increase the risk
of disease expression or to produce a more severe
clinical outcome. The rich variability within
HVS-I compared with the relatively constant
constellation within the gene regions provides
useful criteria for pathogenetic studies. This is
the first study to trace mtDNA HVSI variants in CRC
patients of the Persian population. We concluded
from the tested data that haplogroup K is
considerably more frequent in CRC patients
(P=0.001) (Table I). Thus, mtDNA haplogroup K
might constitute a risk factor for colon cancer.
Our results for haplogroup K are consistent with
a recent study reporting that individuals bearing
haplogroup K have increased risk for breast cancer
[16]. But it is interesting that another research group
recently reported that mtDNA haplogroups K and J
have an apparent protective effect on Parkinson’s
disease [17, 18]. Conversely, haplogroup J has also
been found to increase the risk for disease
expression of Leber’s hereditary optic neuropathy
[19]. In our study we observed that the frequency
of haplogroup U in the control sample population
is half of the frequency of haplogroup J in
the patient population; however it is not statistically
significant (P-value=0.321). 
Also an increased risk for haplogroups K and A
was previously reported by Iranian researchers for
multiple sclerosis patients [20]. We did not find any
relationship between clinical characteristics and
haplogroup K in our patients.
In conclusion, our data suggest an association
of haplogroup K with CRC in Iranian patients.
However, more studies of all types of cancers of both
genders with stratification of the data set by sex are
necessary and also further investigations on
haplotype and other genes must be performed to
shed new light on the molecular pathogenesis of CRC.
In this contribution we found a significant
association of haplogroup K with CRC in Iranian
patients so it can be concluded that mtDNA haplo-
group K might constitute a risk factor for colon cancer.
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